Curia, a contract research, development and manufacturing organization, has unveiled its refreshed brand. The update introduces refined corporate messaging and a new brand hierarchy, highlighting the breadth of Curia’s CDMO capabilities across small molecules, generic APIs and biologics.
 
“This refresh reflects our unwavering commitment to being a trusted ally to our customers,” said Philip Macnabb, CEO of Curia. “Curia has decades of experience in this industry, and we have continually broadened our capabilities to meet the needs of our customers. Our new brand identity clearly communicates not just our offerings, but the unique level of expertise and collaboration we bring as we work to noble purpose to improve patients’ lives.”   
 
The brand refresh includes:
 
Three distinct commercial service logos – Curia has established brand logos for each of its three key service offerings across small molecules, generic APIs and biologics.
Revamped website –The evolved design improves the user experience for clients and prospects.
 
Curia began as AMRI more than 30 years ago with a focus on small molecules, and over time, expanded to offer a blend of global resources and scientific expertise. In 2021, AMRI rebranded as Curia and broadened its capabilities to include biologics with the acquisition of LakePharma and Integrity Bio. This next evolution of its brand strategically highlights Curia’s strengths as a full-service CDMO across modalities.